Another cohort study examined tirzepatide compared to semaglutide and found the absolute difference in weight loss between the two to be 4.3% at six months and 6.9% at 12 months, meaning tirzepatide led to 4.3-6.9% greater weight loss overall
In clinical data, the triple-target Retatrutide gives the largest weight drops, which makes the comparison useful for metabolic research
Significant weight loss may unmask or alter thyroid status, requiring minor levothyroxine dose adjustments
Learn More About Semaglutide What is Semaglutide Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist a synthetic analog of the naturally occurring incretin hormone GLP-1, engineered with a fatty acid side chain that extends its half-life to approximately one week, enabling once-weekly subcutaneous injection
Patients consistently report that food simply becomes less compelling, making the behavioral changes of a weight loss program significantly easier to sustain